Lv3
364 积分 2022-09-14 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
29天前
已完结
Treatment ofEGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors
1个月前
已完结
EGFR‐TKIs plus local therapy demonstrated survival benefit than EGFR‐TKIs alone in EGFR‐mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
1个月前
已完结
ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI
1个月前
已完结
Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy
1个月前
已完结
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR -Mutant Lung Cancer Treated With Osimertinib
1个月前
已完结
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Comparative effectiveness of bevacizumab plus cisplatin‐based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non‐squamous non‐small cell lung cancer patients applying real‐life outcomes
1个月前
已完结
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison
1个月前
已完结
Matching-Adjusted Indirect Treatment Comparison of Tarlatamab Versus Comparator Therapies in England in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Received Two or More Prior Lines of Therapy
1个月前
已完结
皖公网安备34019202002308
